Global Anti-Obesity Drugs Market 2018-2022| Global Increase in the Incidence and Prevalence of Obesity to Boost Demand| Technavio

Technavio analysts forecast the global anti-obesity drugs market to grow at a CAGR of close to 8% by 2022. (Graphic: Business Wire)

LONDON--()--Technavio analysts forecast the global anti-obesity drugs market to grow at a CAGR of close to 8% during the forecast period, according to their latest market research report. However, the growth momentum of the market is expected to decelerate due to a decline in the year-over-year growth.

Research on drugs that target both obesity and type 2 diabetes is one of the major trends being witnessed in the global anti-obesity drugs market 2018-2022. The global epidemic of obesity and type 2 diabetes are metabolic syndromes and associated with comorbidities including hypertension and dyslipidemia, which result in cardiovascular diseases in most of the people worldwide. Also, BMI is a strong indicator of both diabetes and insulin resistance.

This report is available at a USD 1,000 discount for a limited time only: View market snapshot before purchasing

According to Technavio analysts, one of the key factors contributing to the growth of the global anti-obesity drugs market is the worldwide increase in both incidence and prevalence of obesity:

Global anti-obesity drugs market: Worldwide increase in both incidence and prevalence of obesity

Obesity is a major public health concern globally. It has been observed that obesity is associated with health behavior and chronic diseases such as diabetes, hypertension, and cancer. The prevalence and incidence of obesity population worldwide is very high because of the limited efficacy of currently available drugs. The prevalence of obesity remains the highest in the US over the past two decades. Thus, the global increase in the prevalence and incidence of obesity offers huge opportunities for drug manufacturing companies to manufacture innovative and highly effective drugs. Hence, driving the growth of the global anti-obesity drug market.

According to a senior analyst at Technavio, “Research has shown that obesity in adults has steadily increased since the 1980’s. In 2015 and 2016, around 39.6% of American adults over the age of 20 years were considered as obese. In 2017, Egypt had about 19 million obese adults, which is the highest rate worldwide and the US had the highest percentage of obese children. In 2014, it was reported that 51.6% of the EU’s population was overweight.”

Global anti-obesity drugs market: Segmentation analysis

The global anti-obesity drugs market research report provides market segmentation by drugs based on the class of obesity (class I anti-obesity drugs, class II anti-obesity drugs and class III anti-obesity drugs) and by region (the Americas, EMEA, and APAC). It provides an in-depth analysis of the prominent factors influencing the market, including drivers, opportunities, trends, and industry-specific challenges.

The Americas held the largest share of the market in 2017, accounting for 70% share. It was followed by EMEA and APAC respectively. Factors such as increasing prevalence and incidence of obesity in adults and children are expected to drive the market in the Americas, resulting in an increase in the share of the region during the forecast period.

Looking for more information on this market? Request a free sample report

Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.

Some of the key topics covered in the report include:

Market Landscape

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

Market Sizing

  • Market definition
  • Market size and forecast

Five Forces Analysis

Market Segmentation

Geographical Segmentation

  • Regional comparison
  • Key leading countries

Market Drivers

Market Challenges

Market Trends

Vendor Landscape

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Competitive scenario

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team at media@technavio.com.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
www.technavio.com

Release Summary

Technavio analysts forecast the global anti-obesity drugs market to grow at a CAGR of close to 8% by 2022.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
www.technavio.com